Americans have used outdated sunscreen tech while the rest of the world moved forward
For a generation, Americans applied sunscreen formulated with older chemistry while much of the developed world moved on to more effective options — a gap born not of science, but of bureaucratic inertia. This week, the FDA approved bemotrizinol, a broad-spectrum UV filter long established in Europe and Asia, marking the first new sunscreen ingredient cleared in the United States in over 25 years. The approval, made possible by a 2020 congressional reform, arrives as both a practical advance for consumers and a quiet acknowledgment that regulatory systems, like the skin they are meant to protect, can only absorb so much neglect before the damage shows.
- Americans have been using sunscreen technology frozen in time while Europe and Asia moved to superior formulas — a disparity that dermatologists have flagged for years as a quiet public health failure.
- Bemotrizinol, approved in Europe in 1999 and submitted to the FDA in 2005, spent two decades in regulatory limbo, requiring additional studies before the agency would act.
- The ingredient's approval under a 2020 streamlined congressional pathway signals that the FDA's long-stalled sunscreen modernization process may finally be breaking loose.
- Dutch manufacturer DSM will launch the ingredient under the brand name Parsol Shield before year's end, with an 18-month exclusivity window before competitors can follow.
- Broader FDA sunscreen reforms — including SPF caps and stricter UVA standards proposed in 2021 — remain unfinished, leaving open the question of whether this approval is a turning point or an outlier.
For more than 25 years, Americans watched as Europeans and Asians used a sunscreen ingredient that never made it through FDA review. That changed this week when regulators approved bemotrizinol — a chemical protecting skin in Europe, Japan, and South Korea since the late 1990s — marking the first new sunscreen ingredient cleared in the U.S. in over a quarter-century.
The approval came through a streamlined pathway Congress authorized in 2020, designed to cut through the regulatory gridlock that had long paralyzed sunscreen innovation in America. Bemotrizinol passed the FDA's safety thresholds, showing minimal skin irritation and negligible absorption, and has been cleared for use in adults and children as young as six months.
What makes the ingredient notable is what it does that current U.S. options cannot do as cleanly: it blocks both UVA and UVB rays, resists breaking down under sun exposure, and does so without leaving the white cast associated with mineral alternatives like zinc oxide. Dutch manufacturer DSM Nutritional Products will bring it to market as Parsol Shield, with an 18-month exclusivity period before other brands can follow.
The road to approval was long. DSM filed with the FDA in 2005, six years after European authorization. The agency requested additional studies in 2019; DSM complied, and the approval finally came. Advocates like the Environmental Working Group called it a necessary correction, and Health and Human Services Secretary Robert F. Kennedy praised the decision for expanding competition and consumer confidence.
The approval may carry implications beyond a single ingredient. The FDA proposed additional sunscreen standard updates in 2021 — including SPF caps and stricter UVA requirements — that remain pending. Whether bemotrizinol's clearance accelerates that broader modernization, or stands as a rare exception in a system still inclined toward caution, remains to be seen.
For more than a quarter-century, Americans have watched from across the Atlantic as Europeans and Asians used a sunscreen ingredient that the FDA deemed too risky to approve at home. That gap finally closed this week when federal regulators gave the green light to bemotrizinol, a chemical that has protected skin in Europe, Japan, and South Korea since the late 1990s but remained locked out of the U.S. market by regulatory inertia.
The approval, announced Tuesday, represents a rare moment of momentum in the FDA's notoriously sluggish process for updating sunscreen standards. Bemotrizinol is the first new sunscreen ingredient to win FDA clearance in more than 25 years, and it arrived through a streamlined pathway that Congress authorized in 2020—a procedural shortcut that may finally begin to unwind decades of regulatory gridlock. The ingredient meets the agency's safety thresholds, causing minimal skin irritation and showing negligible absorption into the body. The FDA has cleared it for use in adults and children as young as six months.
Dutch manufacturer DSM Nutritional Products will bring bemotrizinol to American shelves under the brand name Parsol Shield, with a market launch expected before year's end. The company will hold exclusive rights for 18 months before other manufacturers can incorporate the ingredient into their own formulations. The timing matters: bemotrizinol fills a gap that has frustrated dermatologists and consumers alike. Unlike the chemical sunscreens currently available in the U.S.—which typically protect against either UVA or UVB rays but not both—bemotrizinol blocks the full spectrum of harmful ultraviolet radiation. Mineral-based alternatives like zinc oxide do offer broad protection, but they leave the distinctive white cast that many people find cosmetically unacceptable. Bemotrizinol delivers both coverage and clarity, and it resists photodegradation more effectively than existing options, meaning the protection holds up longer under sun exposure.
The journey to this approval reveals how far behind the regulatory curve America has fallen. Bemotrizinol won authorization from European authorities in 1999. DSM filed for FDA review six years later, in 2005. The company then spent years waiting, watching consumers abroad embrace the ingredient while American regulators deliberated. In 2019, the FDA requested additional studies. DSM complied, running new trials that finally satisfied the agency's concerns. The delay was not unusual—it reflected a broader pattern of regulatory paralysis that has left American sunscreen technology aging in place while the rest of the developed world moved forward.
David Andrews of the Environmental Working Group, an organization that has spent years pushing the FDA to modernize its sunscreen standards, called the approval a necessary correction. "For decades, Americans have used outdated sunscreen tech while the rest of the world moved forward," he said. The sentiment echoed through official channels. Health and Human Services Secretary Robert F. Kennedy, whose department oversees the FDA, praised the decision for expanding consumer choice and fostering competition in a market that has stagnated under regulatory constraints. "Bemotrizinol has been used safely in Europe for decades, and FDA's action will increase competition and consumer confidence in sunscreen products," Kennedy stated.
The approval also signals that the FDA's broader sunscreen modernization effort, dormant for years, may be gaining traction. In 2011, the agency banned misleading terms like "waterproof" and required all sunscreens to filter both UVA and UVB rays—a baseline that many other countries had already established. In 2021, the FDA proposed additional measures, including caps on SPF numbers and stricter UVA protection standards, but those proposals remain incomplete. Bemotrizinol's approval under the new streamlined process suggests that the regulatory machinery, however slowly, is beginning to turn. The question now is whether this first approval will accelerate the modernization of American sunscreen standards or remain an isolated victory in a system still weighted toward caution over innovation.
Citações Notáveis
For decades, Americans have used outdated sunscreen tech while the rest of the world moved forward. The approval of bemotrizinol will help change that.— David Andrews, Environmental Working Group
Bemotrizinol has been used safely in Europe for decades, and FDA's action will increase competition and consumer confidence in sunscreen products.— Health and Human Services Secretary Robert F. Kennedy
A Conversa do Hearth Outra perspectiva sobre a história
Why did it take 21 years from the European approval to the FDA's decision?
The FDA's system for reviewing sunscreen ingredients was built for a different era. Each new ingredient had to navigate the same lengthy process as a new drug, even though sunscreens are over-the-counter products. There was no fast track. DSM filed in 2005, but the agency kept asking for more data. It wasn't until Congress created a streamlined pathway in 2020 that things actually moved.
So this is really about bureaucratic process, not safety concerns?
Partly. The FDA did have legitimate questions about absorption and irritation. But bemotrizinol had been safely used in Europe for 20 years by the time they approved it here. The caution was real, but it was also excessive—the ingredient had a long track record.
What makes bemotrizinol actually better than what Americans can already buy?
Two things. First, it protects against both UVA and UVB in a single ingredient, so manufacturers don't have to mix multiple chemicals. Second, it doesn't break down as quickly in sunlight, so the protection lasts longer. And it doesn't leave the white residue that mineral sunscreens do.
Will this change prices?
Probably not immediately. DSM has 18 months of exclusivity, so they can set their own price. After that, competition should bring costs down. But the real value isn't price—it's having a product that actually works the way people want it to.
Is this the beginning of real change at the FDA, or just one approval?
It's a signal. The 2021 proposals about SPF caps and stronger UVA standards are still sitting there. If bemotrizinol's approval opens the door for other ingredients and for those standards to finally move forward, then this matters. If it stays isolated, it's just one win in a system that's still broken.